Page last updated: 2024-12-08

lithium chloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lithium Chloride: A salt of lithium that has been used experimentally as an immunomodulator. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lithium chloride : A metal chloride salt with a Li(+) counterion. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID433294
CHEMBL ID69710
CHEBI ID48607
MeSH IDM0027208

Synonyms (102)

Synonym
licl
LOPAC0_000604
EU-0100604
lithium chloride, bioxtra, >=99.0% (titration)
MOLMAP_000071
NCGC00015607-01
lopac-l-4408
wln: li g
nsc-327172
7447-41-8
lithium chloride (licl)
lithium chloride
nsc327172
hsdb 4281
ccris 5924
nsc 327172
chlorku litu [polish]
chlorure de lithium [french]
einecs 231-212-3
luthium chloride
lithium chloride, for molecular biology, >=99%
lithium chloride, anhydrous, beads, -10 mesh, 99.998% trace metals basis
lithium chloride, anhydrous, beads, -10 mesh, >=99.9% trace metals basis
lithium chloride, powder, >=99.99% trace metals basis
NCGC00093980-01
NCGC00093980-02
chloride, lithium
cloruro de litio
lithiumchlorid
lithii chloridum
chlorure de lithium
CHEBI:48607 ,
chembl69710 ,
lithium chloride, puriss. p.a., acs reagent, anhydrous, >=99.0% (at)
lithium chloride, bioultra, for molecular biology, anhydrous, >=99.0% (at)
NCGC00015607-02
L 4408
L0204
L0222
NCGC00015607-04
chlorku litu
chlorolithium
lithium cholride
A838146
HMS3261J10
59217-69-5
lithium chloride, gamma irradiated, 8m
CCG-204693
AKOS015950647
NCGC00015607-03
g4962qa067 ,
unii-g4962qa067
ec 231-212-3
FT-0627896
LP00604
lithium chloride [mi]
lithium chloride [hsdb]
lithium chloride [inci]
lithium muriaticum [hpus]
lithium muriaticum
lithium chloride [who-dd]
AKOS015902822
clli
lithiumchloridegr(anhydrous)
NCGC00261289-01
tox21_500604
KWGKDLIKAYFUFQ-UHFFFAOYSA-M
lithim chloride
lithiumchloride
AKOS024438070
mfcd00011078
DTXSID2025509 ,
lithium chloride, 3-5% in thf
lithium chloride, ultra dry
lithium chloride, puriss. p.a., anhydrous, >=99.0% (at)
lithium chloride, anhydrous, free-flowing, redi-dri(tm), acs reagent, >=99%
lithium chloride, anhydrous, free-flowing, redi-dri(tm), reagentplus(r), 99%
lithium chloride, anhydrous, chunks, 99.99% trace metals basis
lithium chloride, anhydrous
lithium chloride, acs reagent, >=99%
lithium chloride, saj special grade, >=99.0%
lithium chloride, saj first grade, >=98.0%
lithium chloride, reagentplus(r), 99%
lithium chloride, acs grade
lithium chloride, acs reagent
lithium chloride, vetec(tm) reagent grade
sr-01000076252
SR-01000076252-1
lithium chloride, trace metals grade 99.9%
lithium chloride battery grade
BP-13612
lithium chloride (2.3% in tetrahydrofuran, ca. 0.5mol/l)
Q422930
lithium;chloride
bdbm50494542
SDCCGSBI-0050586.P002
NCGC00015607-07
SY002997
lithium chloride (powder)
2m lithium chloride electrolyte, electrode filling solution
dtxcid105509
lithium monochloride

Research Excerpts

Overview

Lithium chloride (LiCl) is an important mood-stabilizing therapeutic agent for bipolar disorders. 40% of the patients develop diabetes insipidus as a side effect. Lithium chloride is a glycogen synthase kinase 3β (GSK-3β) inhibitor.

ExcerptReferenceRelevance
"Lithium chloride (LiCl) is an important mood-stabilizing therapeutic agent for bipolar disorders, which has also been shown to inhibit cancer cell metastasis. "( Lithium chloride inhibits the migration and invasion of osteosarcoma cells by blocking nuclear translocation of phospho-Erk.
Jeon, SH; Kim, JY; Park, HH; Yong, TS, 2021
)
3.51
"Lithium chloride (LiCl) is a widely used and extensively researched drug for the treatment of bipolar disorder (BD). "( Lithium chloride sensitivity connects the activity of PEX11 and RIM20 to the translation of PGM2 and other mRNAs with structured 5'-UTRs.
Al-Gafari, M; Golshani, A; Hajikarimlou, M; Jagadeesan, SK; Moteshareie, H; Samanfar, B; Smith, M; Takallou, S; Tayabali, A, 2022
)
3.61
"Lithium chloride (LiCl) is a compound that induces unpleasant sensations, including visceral discomfort, although its effects on behavior and physiological conditions have also not been investigated extensively in birds."( Effect of lithium chloride on food intake, cloacal temperature, voluntary activity, and crop-emptying rate in chicks.
Cline, MA; Khan, S; Makino, R; Nakatani, A; Tachibana, T, 2022
)
1.85
"Lithium chloride (LiCl) is a widely used drug for the treatment of bipolar disorders, but as a side effect, 40% of the patients develop diabetes insipidus. "( Lithium Chloride and GSK3 Inhibition Reduce Aquaporin-2 Expression in Primary Cultured Inner Medullary Collecting Duct Cells Due to Independent Mechanisms.
Edemir, B; Kaiser, M, 2020
)
3.44
"Lithium chloride is a glycogen synthase kinase 3β (GSK-3β) inhibitor and exert its effects through modulation of nitric oxide pathway."( Lithium reverses the effect of opioids on eNOS/nitric oxide pathway in human umbilical vein endothelial cells.
Dehpour, AR; Esmaeili, J; Mumtaz, F; Nezamoleslami, S; Shafaroodi, H; Sheibani, M, 2020
)
1.28
"Lithium Chloride (LiCl) is a widely prescribed drug for the treatment of bipolar disorder, acute brain injuries, and chronic neurodegenerative diseases."( Lithium chloride functions as Newcastle disease virus-induced ER-stress modulator and confers anti-viral effect.
Kumar, S; Shokeen, K; Srivathsan, A, 2021
)
2.79
"Lithium chloride (LiCl) is an emetic drug that has been used to create animal models of anticipatory nausea and conditioned place aversion. "( Toxin-induced aversive context conditioning: Assessing active aversive behaviors conditioned to the context of an automated activity monitor.
Cross-Mellor, SK; Doobay, M; Kavaliers, M; Ossenkopp, KP; Wah, DTO, 2021
)
2.06
"Lithium chloride (LiCl) is a widely-used medication to treat neurological disorders that has undesirable side effects on the female reproductive system. "( Lithium chloride inhibits StAR and progesterone production through GSK-3β and ERK1/2 signaling pathways in human granulosa-lutein cells.
Bai, L; Chang, HM; Cheng, JC; Chu, G; Leung, PCK; Yang, G, 2018
)
3.37
"Lithium chloride (LiCl) is a drug used to treat bipolar disorder, but has side effects in the female reproductive system. "( Lithium induces follicular atresia in rat ovary through a GSK-3β/β-catenin dependent mechanism.
Mirakhori, F; Shirmohammadian, A; Tafreshi, AP; Zeynali, B, 2013
)
1.83
"Lithium chloride (LiCl) is an FDA-approved drug for bipolar disorder."( Antimanic drug sensitizes breast cancer cell line to ionizing radiation.
Goliaei, B; Khodagholi, F; Nikoofar, A; Rouhani, M, 2014
)
1.12
"Lithium chloride (LiCl) is an activator of Wnt/β-catenin signaling through stabilizing β-catenin."( CTSB promotes porcine preadipocytes differentiation by degrading fibronectin and attenuating the Wnt/β-catenin signaling pathway.
Dong, PY; Mai, Y; Yang, GS; Yang, H; Zhang, ZY; Zheng, XL, 2014
)
1.12
"Lithium chloride is a GSK-3 family inhibitor that has been a mainstay of in vitro and in vivo studies for many years."( Beryllium is an inhibitor of cellular GSK-3β that is 1,000-fold more potent than lithium.
Abdul, AR; Gary, RK; Gorjala, P; Mudireddy, SR, 2014
)
1.12
"Lithium chloride (LiCl), which is a specific inhibitor of glycogen synthase kinase-3β, is known to induce cell cycle arrest at the G2/M phase and to regulate apoptosis. "( Effect of lithium chloride on the production and sialylation of Fc-fusion protein in Chinese hamster ovary cell culture.
Ha, TK; Kim, YG; Lee, GM, 2014
)
2.25
"Lithium chloride is a potential antiviral drug for viruses."( Antiviral effect of lithium chloride on infection of cells by canine parvovirus.
Fang, B; Fu, C; Fu, X; Hong, M; Huang, S; Li, S; Yan, Z; Zhou, P, 2015
)
1.46
"Lithium chloride (LiCl), is a drug used to treat bipolar disorder and has also shown activity against bacterial and viral infections."( In vitro protective efficacy of Lithium chloride against Mycoplasma hyopneumoniae infection.
Feng, ZX; Ishag, HZ; Liu, MJ; Shao, GQ; Wu, YZ; Xiong, QY; Yang, RS, 2016
)
1.44
"Lithium chloride is a therapeutic agent for treatment of bipolar affective disorders. "( Lithium chloride protects retinal neurocytes from nutrient deprivation by promoting DNA non-homologous end-joining.
Ge, J; Ge, Y; Kaminski, JM; Li, F; Lin, J; Liu, X; Liu, Z; Summers, JB; Wang, Z; Yu, K; Zhuang, J, 2009
)
3.24
"Lithium Chloride (LiCl), which is an inhibitor of GSK3β, markedly reduced the TNF-α-stimulated IL-6 release, similar to the results with Wnt3a."( Wnt3a regulates tumor necrosis factor-α-stimulated interleukin-6 release in osteoblasts.
Adachi, S; Kato, K; Kozawa, O; Matsushima-Nishiwaki, R; Minamitani, C; Natsume, H; Otsuka, T; Tokuda, H, 2011
)
1.09
"Lithium chloride (LiCl) is a selective inhibitor of glycogen synthase kinase-3β (GSK-3β), a serine/threonine kinase that regulates many cellular processes, in addition to its role in the regulation of glycogen synthase."( Biphasic dose-dependent effect of lithium chloride on survival of human hormone-dependent breast cancer cells (MCF-7).
Gayathri, G; Ravi Sankar, B; Sangeetha, G; Suganthi, M, 2012
)
1.38
"Lithium chloride (LiCl) is a potent inhibitor of the DNA virus herpes simplex virus but not RNA viruses."( Lithium chloride inhibits the coronavirus infectious bronchitis virus in cell culture.
Harrison, SM; Hiscox, JA; Kaiser, P; Rothwell, L; Tarpey, I, 2007
)
2.5

Effects

Lithium chloride has long been used as a psychiatric medication. Its role in the differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) remains largely unknown. Lithium chloride (LiCl) has been shown to improve the tightness of brain endothelial cell monolayers in vitro.

ExcerptReferenceRelevance
"Lithium chloride (LiCl) has a significant neuroprotective effect in cerebral ischaemia. "( Lithium chloride promotes neural functional recovery after local cerebral ischaemia injury in rats through Wnt signalling pathway activation.
Dan, Y; Junde, Z; Lu, Z; Shan, C; Tingting, L; Yizhen, Z, 2023
)
3.8
"Lithium chloride (LiCl) has a significant neuroprotective effect in cerebral ischaemia. "( Lithium chloride promotes neural functional recovery after local cerebral ischaemia injury in rats through Wnt signalling pathway activation.
Dan, Y; Junde, Z; Lu, Z; Shan, C; Tingting, L; Yizhen, Z, 2023
)
3.8
"Lithium chloride (LiCl) has been widely researched and utilized as a therapeutic option for bipolar disorder (BD). "(
Al-Gafari, M; Allard, D; Golshani, A; Hajikarimlou, M; Jagadeesan, SK; Kazmirchuk, TDD; Moteshareie, H; Nokhbeh, R; Said, KB; Samanfar, B; Smith, M; Takallou, S; Wang, J, 2023
)
2.35
"Lithium chloride has previously been shown to enhance myogenesis and prevent certain forms of muscular dystrophy."( Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia.
Jung, DW; Kim, HJ; Kim, JH; Kim, SW; Lee, JH; Um, J; Williams, DR, 2021
)
2.79
"Lithium chloride has been widely used as a therapeutic mood stabilizer. "( Lithium causes differential effects on postsynaptic stability in normal and denervated neuromuscular synapses.
Barrantes, FJ; Henríquez, JP; Zelada, D, 2021
)
2.06
"Lithium chloride (LiCl) has been shown to improve the tightness of brain endothelial cell monolayers in vitro by inhibition of the GSK-3β enzyme, activation of the Wnt/beta-catenin pathway and regulation of tight junction (TJ) protein expression. "( Effect of Long-term In Vitro Lithium Exposure on mRNA Levels of Claudin-3, CYP1A1, ABCG2 and GSTM3 Genes in the hCMEC/D3 Human Brain Endothelial Cell Line.
Couraud, PO; Declèves, X; Ganeshamoorthy, K; Huilong, L; Scherrmann, JM; Shawahna, R, 2017
)
1.9
"Lithium chloride (LiCl) has been reported to possess antiviral activity against several viruses. "( Antiviral effect of lithium chloride on replication of avian leukosis virus subgroup J in cell culture.
Cheng, X; Nair, V; Qian, K; Qin, A; Shao, H; Yao, Y; Zhang, D, 2018
)
2.25
"Lithium chloride (LiCl) has been reported as a potential antiviral drug for certain viruses."( Antiviral effect of lithium chloride on porcine epidemic diarrhea virus in vitro.
Gao, DS; Li, HJ; Li, YT; Liu, HY; Wang, YS; Zhao, J, 2018
)
1.53
"Lithium chloride (LiCl) has shown neuroprotective effects through glycogen synthase kinase-3β (GSK-3β) inhibition in a variety of central nervous system diseases."( Lithium chloride promoted hematoma resolution after intracerebral hemorrhage through GSK-3β-mediated pathways-dependent microglia phagocytosis and M2-phenotype differentiation, angiogenesis and neurogenesis in a rat model.
Li, R; Liu, Z; Tang, X; Wu, X; Yu, Z; Zhao, S, 2019
)
2.68
"Lithium chloride has demonstrated neuroprotective qualities and therefore shows great potential therapeutic benefit for some neurodegenerative diseases."( Synergistic lithium chloride and glial cell line-derived neurotrophic factor delivery for peripheral nerve repair in a rodent sciatic nerve injury model.
Lin, YC; Marra, KG; Oh, SJ, 2013
)
1.49
"Lithium chloride (LiCl) has been used as a mood stabilizer in the manic depressive disorders treatment. "( LiCl inhibits PRRSV infection by enhancing Wnt/β-catenin pathway and suppressing inflammatory responses.
Fan, HJ; Hao, HP; Li, JR; Mao, X; Ni, B; Sun, MX; Wang, R; Wang, X; Wang, Y; Wen, LB, 2015
)
1.86
"Lithium chloride (LiCl) has long been used as a mood stabilizer for bipolar mood depression patients. "( The iNOS/Src/FAK axis contributes to lithium chloride-mediated macrophage migration.
Chang, MY; Chen, HC; Chien, WC; Hsieh, MY; Lai, MD; Leu, TH; Maa, MC, 2015
)
2.13
"Lithium chloride (LiCl) has long been used as a psychiatric medication; however, its role in the differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) remains largely unknown. "( Lithium Chloride Modulates Adipogenesis and Osteogenesis of Human Bone Marrow-Derived Mesenchymal Stem Cells.
Chen, Y; Pei, F; Tang, L; Zhang, H, 2015
)
3.3
"Lithium Chloride (LiCl) has been used as a canonical Wnt pathway activator due to its ability to inhibit a glycogen synthase kinase-3. "( Effect of lithium chloride on cell proliferation and osteogenic differentiation in stem cells from human exfoliated deciduous teeth.
Osathanon, T; Pavasant, P; Rattanawarawipa, P; Sukarawan, W, 2016
)
2.28
"Lithium chloride (LiCl) has been found to be effective against several DNA viruses, such as Herpes simplex virus and vaccinia virus."( Action mechanisms of lithium chloride on cell infection by transmissible gastroenteritis coronavirus.
Herrler, G; Li, G; Li, X; Meng, F; Ren, X; Wang, C; Yin, J, 2011
)
1.41
"Lithium chloride (LiCl) has been considered to be a potent inhibitor of glycogen synthase kinase-3β (GSK-3β), a serine/threonine kinase that is involved in the control of cell proliferation, differentiation, and apoptosis."( In vitro mechanisms involved in the regulation of cell survival by lithium chloride and IGF-1 in human hormone-dependent breast cancer cells (MCF-7).
Babu, SD; Benson, CS; Ramadoss, S; Ravi Sankar, B; Sangeetha, G; Sathyavathy, A; Suganthi, M, 2012
)
1.34
"Lithium chloride (LiCl) has been shown to demonstrate anticancer properties at supratherapeutic doses. "( Lithium chloride and inhibition of glycogen synthase kinase 3β as a potential therapy for serous ovarian cancer.
Goodfellow, PJ; Mutch, DG; Novetsky, AP; Powell, MA; Thaker, PH; Thompson, DM; Zighelboim, I, 2013
)
3.28
"Lithium chloride (LiCl) has been shown to decrease gastric acid secretion and protect against ethanol-induced hemorrhagic gastritis in the rat. "( Effect of LiCl on gastric acid secretion and mucosal barrier function.
Boedeker, HB; Harmon, JW; Johnson, LF; Lillemoe, KD; Wong, RK, 1983
)
1.71
"Lithium chloride has been used in many studies of conditioning to induce taste aversion behaviour, and in some experiments investigating conditioning effects on immunity it has been used on the assumption that it is immunologically neutral. "( Lithium chloride and immunomodulation in taste aversion conditioning.
Bull, DF; Gauci, M; Husband, AJ; King, MG; Schedlowski, M, 1992
)
3.17
"Lithium chloride has been shown to cause granulocytosis both in vivo and in vitro."( Effect of adenine nucleotides on granulopoiesis and lithium-induced granulocytosis in long-term bone marrow cultures.
Berne, RM; Gualtieri, RJ; Huster, WJ; McGrath, HE; Quesenberry, PJ, 1986
)
0.99

Actions

ExcerptReferenceRelevance
"Lithium chloride can inhibit the proliferation of K562 cells and cause the apoptosis of K562 cells."( [Effects of lithium chloride on the proliferation and apoptosis of K562 leukemia cells].
He, Q; Tang, HR, 2003
)
2.14

Treatment

Lithium chloride has shown neuroprotective effects through glycogen synthase kinase-3β inhibition in a variety of central nervous system diseases. Lithium chloride treatment reduces IRI in many organs including liver.

ExcerptReferenceRelevance
"Lithium chloride treatment reduces IRI in many organs including liver."( Induction of autophagy reduces ischemia/reperfusion injury in steatotic rat livers.
Boettcher, M; Dahmen, U; Dirsch, O; Fang, H; Kan, C; Liu, A, 2017
)
1.18
"Lithium chloride, a classical treatment for bipolar disorder, has shown neuroprotective effects through glycogen synthase kinase-3β inhibition in a variety of central nervous system diseases, including stroke."( The neuroprotective effect of lithium chloride on cognitive impairment through glycogen synthase kinase-3β inhibition in intracerebral hemorrhage rats.
Jiang, C; Li, R; Li, W; Liu, Z; Tang, X; Zhao, S, 2018
)
1.49
"Lithium chloride-treated birds had a 22% reduction in stiffness compared with control in the femora (P=0.02) without a corresponding reduction in elastic modulus."( Effect of daily lithium chloride administration on bone mass and strength in growing broiler chickens.
Adams, DJ; Darre, M; Eschbach, M; Glynn, EA; Govoni, KE; Harvey, BM; Kotha, S; Mancini, R; Ramanathan, R, 2015
)
1.48
"Lithium chloride treatment of human skin fibroblasts from control and Glut-1 DS patients produced a 45% increase in glucose uptake."( Murine Glut-1 transporter haploinsufficiency: postnatal deceleration of brain weight and reactive astrocytosis.
De Vivo, DC; Di Nardo, A; Engelstad, K; Goldman, JE; Sahin, M; Schobel, S; Ullner, PM; Wang, D; Yang, H, 2009
)
1.07
"Lithium chloride treatment increased urine volume and decreased osmolality in both WT and AQP2-CNT-KO mice."( Genetic ablation of aquaporin-2 in the mouse connecting tubules results in defective renal water handling.
Fenton, RA; Kortenoeven, ML; Miller, RL; Pedersen, NB; Rojek, A, 2013
)
1.11
"Lithium chloride (LiCl) treatment activated Wnt signaling in osteoblasts, inhibited myeloma bone disease, and decreased tumor burden in bone, but increased tumor growth when 5TGM1 cells were inoculated subcutaneously."( Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
Edwards, CM; Edwards, JR; Esparza, J; Grubbs, B; Lwin, ST; McCluskey, B; Mundy, GR; Munoz, S; Oyajobi, BO, 2008
)
1.07
"Both lithium chloride and quinine treatments gave rise to a slow rate of eating accompanied by a disordered temporal sequence of eating, grooming and resting."( Behavioural structure and mechanisms of anorexia: calibration of natural and abnormal inhibition of eating.
Blundell, JE; Hill, AJ; Rogers, PJ, 1985
)
0.72
"As treatment with lithium chloride (LiCl) can restore passaged chondrocytes in monolayer, in this study, we investigated whether this approach would be effective in 3D culture and restore chondrocyte mechanosensitivity."( Lithium chloride-induced primary cilia recovery enhances biosynthetic response of chondrocytes to mechanical stimulation.
Chiu, LLY; Momin, A; Soave, A; Waldman, SD, 2022
)
2.49
"Treatment with lithium chloride induced autophagy and apoptosis in recombinant insect cells and led to increases in the yields of secreted antibodies."( Effects of lithium on the secretory production of recombinant antibody from insect cells.
Katsuda, T; Ohmuro-Matsuyama, Y; Yamaji, H, 2019
)
0.85
"Treatment with lithium chloride caused a robust increase in interleukin-10, preserved ψ(m), and markedly decreased all other parameters with the effect being most prominent for hearts perfused at the high pressure."( Pressure overload regulates expression of cytokines, γH2AX, and growth arrest- and DNA-damage inducible protein 153 via glycogen synthase kinase-3β in ischemic-reperfused hearts.
Baban, B; Liu, JY; Mozaffari, MS, 2013
)
0.73
"Rats treated with lithium chloride for 6 weeks have been reported to demonstrate reduced turnover of arachidonic acid (AA) in brain phospholipids, and decreases in mRNA and protein levels, and enzyme activity, of AA-selective cytosolic phospholipase A(2)(cPLA(2)). "( Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain.
Bosetti, F; Chang, MC; Contreras, MA; Rapoport, SI; Rintala, J; Rosenberger, TA; Seemann, R, 2002
)
0.65
"Pretreatment with lithium chloride at the threshold concentrations enhanced the inhibitory effects of verapamil on diaphragmatic contractions elicited either indirectly or directly."( The myoneural effects of lithium chloride on the nerve-muscle preparations of rats. Role of adenosine triphosphate-sensitive potassium channels.
Abdel-Zaher, AO, 2000
)
0.93

Toxicity

A single, large, toxic dose of lithium chloride (LiCl) caused necrosis of the distal convoluted tubules, which was visible by light microscopy in 30 min. The necrosis developed in 1 h, and had disappeared by the next day. LD50 and therapeutic index of LiCl were 255 μg/kg and TI≤3.

ExcerptReferenceRelevance
"We studied the ability of lambs to select safe foods in the presence of harmful foods."( Food aversion learning: ability of lambs to distinguish safe from harmful foods.
Burritt, EA; Provenza, FD, 1989
)
0.28
" These findings are in agreement with previous observations suggesting that manganese increases toxic products originating from dopamine catabolism."( Role of dopamine in manganese neurotoxicity.
Cappabianca, V; Groppetti, A; Parati, EA; Parenti, M; Rusconi, L, 1988
)
0.27
" In relation to age, LD50 was significantly higher in rats of 6 weeks after oral administration than LD50 in rats of 3 and 6 months."( Effect of age and route of administration on LD50 of lithium chloride in the rat.
Petersen, KP, 1980
)
0.51
" Diallel cross analysis was used to investigate the genetic properties of the mouse strains in responding to the toxic effects of lithium and in regulating its levels in these tissues, excreta, and urine."( Genetic basis for lithium toxicity and its relationship with tissue distribution: a diallel cross analysis of six strains of mice.
El-Kassem, M; Singh, SM, 1983
)
0.27
" The concentration of Li+ found in urine and excreta was positively correlated with resistance (time to death at 900 mg/kg LiCl) to the toxic effect of lithium."( Strain dependent rate of Li+ elimination associated with toxic effects of lethal doses of lithium chloride in mice.
El-Kassem, M; Singh, SM, 1983
)
0.49
"A taste aversion test was used to evaluate the toxic effects of aflatoxin (AF) B1 which is considered to be one of the most potent hepatocarcinogens known."( Evaluation of the toxic effects of aflatoxin B1 with a taste aversion paradigm in rats.
Llewellyn, GC; Porter, JH; Rappold, VA,
)
0.13
" In addition to blocking sulfate assimilation by product inhibition of PAPS reductase, PAP accumulation may have other unidentified toxic effects."( The yeast HAL2 nucleotidase is an in vivo target of salt toxicity.
Bellés, JM; Murguía, JR; Serrano, R, 1996
)
0.29
" A single, large, toxic dose of lithium chloride (LiCl) caused necrosis of the distal convoluted tubules, which was visible by light microscopy in 30 min, had fully developed in 1 h, and had disappeared by the next day."( Prevention of lithium nephrotoxicity in a novel one-hour model in rats.
Cooper, TB; Katof, B; Levine, S; Meister, A; Saltzman, A, 1998
)
0.58
"To determine the pharmacokinetics and toxic effects associated with IV administration of lithium chloride (LiCl) to conscious healthy horses."( Pharmacokinetics and toxic effects of lithium chloride after intravenous adminstration in conscious horses.
Black, WD; Hatfield, CL; Lemke, KA; McDonell, WN, 2001
)
0.8
" Behavioral and systemic toxic effects of LiCl were also assessed."( Pharmacokinetics and toxic effects of lithium chloride after intravenous adminstration in conscious horses.
Black, WD; Hatfield, CL; Lemke, KA; McDonell, WN, 2001
)
0.58
" Peak serum concentrations were less than steady-state serum concentrations that reportedly cause toxic effects in other species."( Pharmacokinetics and toxic effects of lithium chloride after intravenous adminstration in conscious horses.
Black, WD; Hatfield, CL; Lemke, KA; McDonell, WN, 2001
)
0.58
" A useful model for studying memory formation is gustatory memory, a type of memory in which a novel taste may become either safe by not being followed by negative consequences (attenuation of neophobia, AN), or aversive by being followed by post-digestive malaise (conditioned taste aversion, CTA)."( Safe taste memory consolidation is disrupted by a protein synthesis inhibitor in the nucleus accumbens shell.
Bermúdez-Rattoni, F; Guzmán-Ramos, K; Pedroza-Llinás, R; Ramírez-Lugo, L; Zavala-Vega, S, 2009
)
0.35
" We next examined the response of 48 h pretreated cultures to a toxic level of glutamate."( Estradiol and lithium chloride specifically alter NMDA receptor subunit NR1 mRNA and excitotoxicity in primary cultures.
Valdés, JJ; Weeks, OI, 2009
)
0.71
" A number of rare, potentially serious neurological adverse effects have been reported, including extrapyramidal symptoms, 'pseudotumour cerebri' or occasionally cerebellar symptoms."( Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety.
Aubry, JM; Grandjean, EM, 2009
)
0.35
" Conversely, known activators of autophagy, such as lithium and rapamycin, displayed neuroprotection against this toxic compound."( Role of autophagy inhibitors and inducers in modulating the toxicity of trimethyltin in neuronal cell cultures.
Biagioni, F; Fabrizi, C; Fornai, F; Fumagalli, L; Lenzi, P; Pompili, E; Somma, F, 2012
)
0.38
"Prion protein (PrP) mislocalized in the cytosol has been presumed to be the toxic entity responsible for the neurodegenerative process in transmissible spongiform encephalopathies (TSE), also called prion diseases."( Stabilization of microtubular cytoskeleton protects neurons from toxicity of N-terminal fragment of cytosolic prion protein.
Nieznanska, H; Nieznanski, K; Zajkowski, T, 2015
)
0.42
" LD50 and therapeutic index of lithium chloride were 255 μg/kg and TI≤3, respectively."( Toxic Effects of Lithium Chloride during Early Neonatal Period of Rat Development.
Bannova, AV; Dygalo, NN; Menshanov, PN, 2016
)
1.06

Pharmacokinetics

ExcerptReferenceRelevance
" The mean plasma lithium half-life (t1/2) following the single intravenous dose was 21."( Pharmacokinetics of lithium in the dog.
Davis, LE; Koritz, GD; Rosenthal, RC, 1986
)
0.27
"The pharmacokinetic characteristics of lithium and the profile of plasma lithium concentration at steady state in both the mouse and the rat have been determined."( The pharmacokinetic profile of lithium in rat and mouse; an important factor in psychopharmacological investigation of the drug.
De Souza, R; Goodwin, GM; Green, AR; Wood, AJ, 1986
)
0.27
" The half-life of plasma disappearance of valproate was 25% reduced by lithium pretreatment (0."( Effects of lithium on the pharmacokinetics of valproate in rats.
Ida, S; Nishimoto, A; Shibata, S; Sugawara, A; Takiguchi, Y; Yokota, M; Yoshioka, H, 2000
)
0.31
" Half-life was 43."( Pharmacokinetics and toxic effects of lithium chloride after intravenous adminstration in conscious horses.
Black, WD; Hatfield, CL; Lemke, KA; McDonell, WN, 2001
)
0.58
" Knowledge of Li distribution and its regional pharmacokinetic properties in the living brain is of value in localizing its action in the brain."( Pharmacokinetics of lithium in rat brain regions by spectroscopic imaging.
Lyon, M; Pi, J; Ramaprasad, S; Ripp, E, 2005
)
0.33

Compound-Compound Interactions

Lithium chloride combined with hUCB-SCs transplantation may accelerate functional recovery of the hindlimbs in rats with complete transection of the spinal cord.

ExcerptReferenceRelevance
" If pentobarbital was the CS and d-amphetamine or nicotine sulfate the US, then after about four drug-drug pairings the pentobarbital CS produced a higher heart rate (HR) than control conditions."( Drug-drug heart rate conditioning in rats: effective USs when pentobarbital is the CS.
Reilly, S; Revusky, S, 1992
)
0.28
" Comparison of backward and long-delayed controls in a drug-drug procedure that used a taste aversion test revealed that both forward and delayed pairings can produce attenuated aversions in relation to a backward group regardless of whether the unconditional stimulus is amphetamine (Experiment 1) or lithium chloride (Experiment 2)."( Methodological issues in drug-drug conditioning in rats: nonassociative factors in heart rate and avfail.
Biederman, GB; Davey, VA, 1991
)
0.46
"The safety and tolerability of clozapine combined with lithium were investigated because of potential additive risks as well as frequent usage in clinical practice."( Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder.
Klapper, MH; Malloy, FW; Small, JG; Steadman, TM, 2003
)
0.32
"To evaluate the effects of high-frequency electrical stimulation (HFS) in both ventral hippocampi, alone and combined with a subeffective dose of antiepileptic drugs, during the status epilepticus (SE) induced by lithium-pilocarpine (LP)."( Antiepileptic drugs combined with high-frequency electrical stimulation in the ventral hippocampus modify pilocarpine-induced status epilepticus in rats.
Alcantara-Gonzalez, D; Cuellar-Herrera, M; Neri-Bazan, L; Peña, F; Rocha, L, 2010
)
0.36
" One minute following pilocarpine injection, HFS (pulses of 60 mus width at 130 Hz at subthreshold intensities and applied during 3 h) was applied alone or combined with subeffective doses of antiepileptic drugs."( Antiepileptic drugs combined with high-frequency electrical stimulation in the ventral hippocampus modify pilocarpine-induced status epilepticus in rats.
Alcantara-Gonzalez, D; Cuellar-Herrera, M; Neri-Bazan, L; Peña, F; Rocha, L, 2010
)
0.36
" This effect was not evident when HFS was combined with phenytoin (33."( Antiepileptic drugs combined with high-frequency electrical stimulation in the ventral hippocampus modify pilocarpine-induced status epilepticus in rats.
Alcantara-Gonzalez, D; Cuellar-Herrera, M; Neri-Bazan, L; Peña, F; Rocha, L, 2010
)
0.36
"To observe the effects of lithium chloride combined with human umbilical cord blood mesenchymal stem cell (hUCB-SCs) transplantation in the treatment of spinal cord injury in rats."( [Lithium chloride combined with human umbilical cord blood mesenchymal stem cell transplantation for treatment of spinal cord injury in rats].
Deng, XY; Jin, DD; Lu, KW; Zhou, RP, 2010
)
1.57
" Lithium chloride combined with hUCB-SCs transplantation may accelerate functional recovery of the hindlimbs in rats with complete transection of the spinal cord."( [Lithium chloride combined with human umbilical cord blood mesenchymal stem cell transplantation for treatment of spinal cord injury in rats].
Deng, XY; Jin, DD; Lu, KW; Zhou, RP, 2010
)
2.18
" To judge this hypothesis, the therapeutic effects of Wnt signaling activator lithium chloride (LiCl) combined with the currently used immunosuppressor cyclosporine A (CsA) on mice with AA in vivo was investigated."( [Therapeutic effect of lithium chloride combined with cyclosporine A on mouse model with aplastic anemia].
Dai, YL; Huang, LF; Liu, WL; Zhang, N, 2012
)
0.92
" Therefore, in the present study, the neuroprotective effects and mechanisms of vit-D alone or in combination with lamotrigine have been evaluated in the lithium-pilocarpine model of SE in rats."( Neuroprotective effects of vitamin D alone or in combination with lamotrigine against lithium-pilocarpine model of status epilepticus in rats.
Abdel-Wahab, AF; Afify, MA; Al Ghamdi, SS; Bamagous, GA; ElSawy, NA; Ibrahim, IAA; Mahfoz, AM; Shahzad, N, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" Mean bioavailability was 78."( Pharmacokinetics of lithium in the dog.
Davis, LE; Koritz, GD; Rosenthal, RC, 1986
)
0.27

Dosage Studied

Focal demineralization of bone tissue with local dosed vacuum and 2% lithium chloride electrophoresis was tried in 40 white rats (21 reference ones and 19 experimental) Two groups of rats were injected with lithium chloride intraperitoneally, twice daily at 09:00 and 16:00 h, for 2 and 7 days at a dosage of 2.

ExcerptRelevanceReference
" We now report that LiCl pretreatment shifted the antinociceptive dose-response curve produced by the opioid agonists morphine, [D-Ala2, MePhe4, Gly5-ol]enkephalin (DAMGO) and sufentanil in inverse order of their intrinsic efficacy."( Opioid efficacy is linked to the LiCl-sensitive, inositol-1,4,5-trisphosphate-restorable pathway.
Connelly, CD; Martinez, RP; Raffa, RB, 1992
)
0.28
"When lithium serum levels were within the (human) therapeutic range, young and old adult male and female rats (housed singly or in groups) all displayed faster limbic seizure onset times in response to a muscarinic cholinergic agonist (pilocarpine 20 mg/kg) if a single systemic dosage of chlorpromazine was injected 24 hours previously."( Cholinergic rebound after chlorpromazine exacerbates lithium muscarinic-induced limbic seizures in rats: implications for psychiatric treatment.
Bureau, YR; Persinger, MA, 1991
)
0.28
" Its dose-response ran roughly parallel to that of a bafilomycin A1-induced lysosomal pH increase."( Induction of neurite outgrowth of PC12 cells by an inhibitor of vacuolar H(+)-ATPase, bafilomycin A1.
Ohkuma, S; Tamura, H, 1991
)
0.28
" High dosage of lithium, the intraperitoneal route, and an intermittent schedule of administration were required to achieve suppression of EAE."( Inhibition of experimental allergic encephalomyelitis by lithium chloride: specific effect or nonspecific stress?
Levine, S; Saltzman, A,
)
0.38
"Focal demineralization of bone tissue with local dosed vacuum (exposure of up to 20 sec) and 2% lithium chloride electrophoresis (8 sessions daily, 10 min exposure) was tried in 40 white rats (21 reference ones and 19 experimental)."( [Focal demineralization of the cortical plate of the jaw and its experimental reversibility based on microphotometry data].
Burdukov, PM; Buriakovskiĭ, SA; Gvozdeva, LM; Simanovskaia, EIu,
)
0.35
"In the first experiment a conditioned taste aversion paradigm was used to characterize a dose-response curve for the aversive properties of nicotine in male Sprague-Dawley rats."( Characterization of a dose-response curve for nicotine-induced conditioned taste aversion in rats: relationship to elevation of plasma beta-endorphin concentration.
Gilbert, DG; Jensen, RA; Landrum, TA; Meliska, CJ; Szary, AB, 1990
)
0.28
" Dose-response curves to carbachol and 5-HT showed that lithium treatment reduced the maximal agonist response without altering the EC50 value."( Subacute and chronic in vivo lithium treatment inhibits agonist- and sodium fluoride-stimulated inositol phosphate production in rat cortex.
Godfrey, PP; Grahame-Smith, DG; McClue, SJ; White, AM; Wood, AJ, 1989
)
0.28
" We report here the results of dose-response studies (0."( In vitro effect of lithium on carbamazepine-induced inhibition of murine and human bone marrow-derived granulocyte-macrophage, erythroid, and megakaryocyte progenitor stem cells.
Gallicchio, VS; Hulette, BC, 1989
)
0.28
" Disruptions in the circadian rhythm of food intake failed to show any dose-response relation."( Lithium chloride SCN injection alters the circadian rhythm of food intake.
Badgaiyan, RD; Maini, BK; Marya, RK; Reghunandanan, R; Reghunandanan, V, 1989
)
1.72
"NaCl, LiCl, NH4Cl and KCl inhibit the equilibrium binding of peptide agonists at each of the mu-, delta- and kappa-sites; the orders of potencies and the slopes of the dose-response curves are site-dependent."( Site-dependent effects of ions on mu-, delta- and kappa-opioid binding in suspensions of guinea-pig brain membranes.
Kosterlitz, HW; Paterson, SJ; Robson, LE, 1986
)
0.27
" The appearance of eating and pica at the same dosage suggested that rats may eat food as well as a nonnutritive substance as a species-specific reaction to illness and that postdrug feeding, including that observed after 2DG, is an insufficient condition for concluding that a treatment produces no internal distress."( Patterns of increased and decreased ingestive behavior after injections of lithium chloride and 2-deoxy-D-glucose.
Leitner, C; Watson, PJ, 1988
)
0.51
" The relative activities of these monovalent salts and the slopes of the dose-response curves are site-dependent."( Control by cations of opioid binding in guinea pig brain membranes.
Kosterlitz, HW; Paterson, SJ; Robson, LE, 1986
)
0.27
" After chronic withdrawal of TSH from the growth medium, the magnitude of the response to NE is considerably reduced; however, there is no substantial shift in the dose-response curve."( Norepinephrine and thyroid-stimulating hormone induce inositol phosphate accumulation in FRTL-5 cells.
Alling, DW; Bone, EA; Grollman, EF, 1986
)
0.27
" This sensitivity depends upon the administered dosage and chemoreactivity of the structural brain elements, conditioned by an involvement of different mediator processes, as well as by the character of intracentral interrelationships according to the principle of direct and inverse connections."( [Mechanisms of the central action of lithium].
Sinitskiĭ, VN; Usherenko, LS, 1981
)
0.26
" Significant changes in the thyroid parenchyma proper and in the population of parafollicular or C cells were recorded in response to the increased dosage of the substance injected."( [Morphofunctional changes in the thyroid glands of rats following lithium chloride administration].
Glumova, VA; Kuznetsova, VM; Petrov, NM; Semenov, VV, 1981
)
0.5
"Lithium chloride was given intraperitoneally to dogs at a dosage of 125 mg/kg body weight for three days."( The effect of lithium chloride on renal structure and sodium-potassium-adenosine triphosphatase activity in dogs.
Easley, JR, 1982
)
2.07
" Injection of a single dosage of ethanol into mice pretreated with LiCl for 14 days enhanced spontaneous locomotor activity for the initial 60 min of testing compared to respective control."( Behavioral, metabolic and histological aspects of lithium and ethanol interaction.
Frost, RE; Messiha, FS; Sproat, HF, 1983
)
0.27
" Mortality score indicates a profound lethal effect during administration of LiCl with the high dosage of the chlorpromazine used which was persistent during drug withdrawal."( Effect of alkali metals on chlorpromazine toxicity in the mouse.
Messiha, FS; Sproat, HF, 1983
)
0.27
" One group was given an intraperitoneal injection daily of CPZ HCl, 5 mg/kg for 4 days followed by 4 more days of a daily dosage of 10 mg/kg."( Chlorpromazine and lithium interaction: a biochemical and histological study.
Messiha, FS; Sproat, HF; Striegler, RL, 1983
)
0.27
" In dose-response studies in which the concentration of each component of this serum-free medium was varied in turn, the addition of LiCL (10 mM) enhanced growth at most concentrations of each factor."( Growth effect of lithium on mouse mammary epithelial cells in serum-free collagen gel culture.
Bern, HA; Imagawa, W; Nandi, S; Tomooka, Y, 1983
)
0.27
" The dose-response curve for the initial rate of cytosolic free Ca2+ increase was very similar to those obtained for the initial rates of Ins-P3 production and PtdIns-4,5-P2 breakdown."( Relationship between inositol polyphosphate production and the increase of cytosolic free Ca2+ induced by vasopressin in isolated hepatocytes.
Alexander, J; Thomas, AP; Williamson, JR, 1984
)
0.27
" In addition, there was a dose-response relationship between the doses of aflatoxin and the level of aversion with the AF-High group demonstrating the most marked aversion throughout all saccharin tests."( Evaluation of the toxic effects of aflatoxin B1 with a taste aversion paradigm in rats.
Llewellyn, GC; Porter, JH; Rappold, VA,
)
0.13
" Although this dose-response relationship was evident for both males and females, the minimal effective dose for inducing an aversion was lower for males, an effect consistent with previous work examining sex differences in taste aversion learning."( Sex differences in taste aversion learning: an analysis of the minimal effective dose.
Dacanay, RJ; Mastropaolo, JP; Olin, DA; Riley, AL,
)
0.13
" Active compounds exhibited an inverted U-shaped dose-response curve."( Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
Butler, DE; L'Italien, YJ; Marriott, JG; Nordin, IC; Poschel, PH; Zweisler, L, 1984
)
0.27
" All active compounds gave inverted U-shaped dose-response curves."( Cognition-activating properties of 3-(Aryloxy)pyridines.
Butler, DE; Marriott, JG; Poschel, BP, 1981
)
0.26
" In experiment 3, explants were incubated in the presence of oxytocin or arginine vasopressin at 10(-9) to 10(-6) M to establish dose-response curves for the activation of PLC and release of PGF2 alpha."( Cellular mechanisms mediating the stimulation of ovine endometrial secretion of prostaglandin F2 alpha in response to oxytocin: role of phospholipase C and diacylglycerol.
Brockman, JA; Hayes, SH; Lee, JS; Lowberger, LL; Silvia, WJ; Trammell, DS, 1994
)
0.29
" Cattle dosed with the higher levels of LiCl formed aversions more rapidly in both trials than those dosed at lower levels."( Influence of cattle age, lithium chloride dose level, and food type in the retention of food aversions.
Cheney, CD; Ralphs, MH, 1993
)
0.59
" In the yeast Saccharomyces cerevisiae we have isolated a gene, HAL2, which upon increase in gene dosage improves growth under NaCl and LiCl stresses."( Salt tolerance and methionine biosynthesis in Saccharomyces cerevisiae involve a putative phosphatase gene.
Gaxiola, R; Gläser, HU; Montrichard, F; Serrano, R; Surdin-Kerjan, Y; Thomas, D, 1993
)
0.29
" The pretreatment with 50 and 100 mg/kg zingicomb attenuated the LiCl-produced CPA, whereas a dosage of 10 mg/kg had no effect."( Blockade of lithium chloride-induced conditioned place aversion as a test for antiemetic agents: comparison of metoclopramide with combined extracts of Zingiber officinale and Ginkgo biloba.
Frisch, C; Häcker, R; Hasenöhrl, RU; Huston, JP; Mattern, CM, 1995
)
0.67
" The type of abnormity induced seemed to depend on the time and/or the dosage of LiCl exposure."( LiCl-induced malformations of the eyes and the rostral CNS in Xenopus laevis.
Malz, CR; Meyer, DL; Michel, H; Pritz-Hohmeier, S; Reichenbach, A, 1997
)
0.3
" At this concentration, candesartan only produces a slight rightward shift of the angiotensin II dose-response curve."( The effects of candesartan on human AT1 receptor-expressing Chinese hamster ovary cells.
De Backer, JP; Fierens, FL; Vanderheyden, PM; Vauquelin, G, 1999
)
0.3
" We have tested this hypothesis by: 1) demonstrating an extremely high potency of nordidemnin as an inhibitor of myo-inositol uptake in primary cultures of mouse astrocytes; and 2) determining the dose-response correlation of a nordidemnin-induced decrease in the latency before appearance of seizures in the lithium-pilocarpine test after intracerebroventricular injection of minute samples (10 microl) of virtually isotonic saline solution."( Nordidemnin potently inhibits inositol uptake in cultured astrocytes and dose-dependently augments lithium's proconvulsant effect in vivo.
Belmaker, RH; Berkin, V; Bersudsky, Y; Einat, H; Hertz, L; Wolfson, M, 2000
)
0.31
" FMRFamide and FLRFamide had similar dose-response curve patterns with thresholds at 10(-9) mol l(-1) but FLRFamide was more potent than FMRFamide."( Excitation evoked by FMRFamide and FLRFamide in the heart of Buccinum undatum and evidence for inositol 1,4,5-trisphosphate as an RF-tetrapeptide second messenger.
Ellis, AM; Huddart, H, 2000
)
0.31
" An increase dosage of ZDS1, or of genes involved in cell wall assembly and in secretion (RHO1 and SR077, respectively), partially suppresses the sensitivity of rpb4delta cells to high temperature, heat shock and stationary phase."( Multiple cellular processes affected by the absence of the Rpb4 subunit of RNA polymerase II contribute to the deficiency in the stress response of the yeast rpb4(delta) mutant.
Bourbonnais, Y; Faucher, N; Larouche, C; Pallotta, D, 2001
)
0.31
" Tremor activity was assessed weekly, quantitatively by accelerometry and qualitatively with the Dosage Record and Treatment Emergent Symptom Scale."( Changes in quantitatively assessed tremor during treatment of major depression with lithium augmented by paroxetine or amitriptyline.
Bauer, M; Jobert, M; Müller-Oerlinghausen, B; Zaninelli, R, 2001
)
0.31
" The comparison of CCK-8 and JMV-180 dose-response curves of amylase release to those of PtdIns and PtdOH labelling with [(32)P]-Pi showed the existence of an amplification mechanism between phospholipase C and amylase release for both agonists."( The cholecystokinin analogues JMV-180 and CCK-8 stimulate phospholipase C through the same binding site of CCK(A) receptor in rat pancreatic acini.
Claro, E; Ramos, B; Salido, GM; Sarri, E, 2001
)
0.31
" At the end of the double-blind phase, the blinded medication (lithium in 14 patients, placebo in 8 patients) was tapered off over a 1-week period, while the antidepressant was continued at the same dosage for another 4 weeks."( How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression.
Adli, M; Bauer, M; Berghöfer, A; Bschor, T; Kunz, D; Müller-Oerlinghausen, B; Ströhle, A, 2002
)
0.31
"5 mg daily until a total dosage of either 75 mg or 100 mg was obtained."( Lamotrigine use in geriatric patients with bipolar depression.
Conn, DK; Robillard, M, 2002
)
0.31
" One patient did develop coarse hand tremor that improved when the lamotrigine dosage was decreased."( Lamotrigine use in geriatric patients with bipolar depression.
Conn, DK; Robillard, M, 2002
)
0.31
" Of interest was a determination of which variables might show a dose-response relationship in LiCl-induced conditioned place aversions."( Dose response effects of lithium chloride on conditioned place aversions and locomotor activity in rats.
Kavaliers, M; Ossenkopp, KP; Tenk, CM, 2005
)
0.63
" Mortality was not affected by the dosage of paraldehyde."( Outcome of status epilepticus in immature rats varies according to the paraldehyde treatment.
Kubová, H; Mares, P; Redkozubova, O; Rejchrtová, J, 2005
)
0.33
" Effective dosage of this extract was wider than that of a well-known western neuroprotective medicine lithium chloride (LiCl)."( Neuroprotective effects of anti-aging oriental medicine Lycium barbarum against beta-amyloid peptide neurotoxicity.
Chang, RC; Che, CM; Lai, SW; Leung, SK; So, KF; Yu, MS; Yuen, WH; Zee, SY,
)
0.35
" After having equated drug dosage in terms of conditioned taste avoidance, 13-day-old rats were given a single pairing of a novel taste (saccharin) and either LiCl or ethanol (2."( A comparison between taste avoidance and conditioned disgust reactions induced by ethanol and lithium chloride in preweanling rats.
Arias, C; Molina, JC; Pautassi, RM; Spear, NE, 2010
)
0.58
" Herein, we report one of the first applications of the QUEST-C method to quantify the exfiltration in a continuously operating sewer by dosing two chemical tracers, sodium bromide (NaBr) and lithium chloride (LiCl)."( Quantification of sewer leakage by a continuous tracer method.
Giulianelli, M; Prigiobbe, V, 2011
)
0.56
"  The results support and expand previous findings that lithium should be dosed high enough to achieve plasma levels ≥0."( The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144)
Nolen, WA; Weisler, RH, 2013
)
0.39
" To investigate a role for instrumental punishment in CTA, we present 2 tastants sequentially ("sucrose then NaCl" or "NaCl then sucrose") in a daily alternating and counterbalanced order to rats with an explicit positive contingency between the dosage of the lithium chloride (LiCl) administered and the amount of 1 tastant drunk on that trial."( Conditioned taste aversion as instrumental punishment.
Hsiao, S; Li, JS; Li, KC, 2013
)
0.57
" However, side effects as well as the narrow therapeutic dosing range often complicate its use."( Temporal association as a prerequisite factor of valsartan-induced lithium toxicity.
Giannakopoulos, P; Lazarczyk, MJ, 2014
)
0.4
"In contrast to previous reports, the toxicity in our patient occurred not upon introduction or titration of lithium or valsartan but after subtle modifications in daily dosing schedule for lithium."( Temporal association as a prerequisite factor of valsartan-induced lithium toxicity.
Giannakopoulos, P; Lazarczyk, MJ, 2014
)
0.4
" We found that α6 KO mice exhibited a rightward shift in the nicotine dose-response curve compared with WT littermates but that α4 KO failed to show nicotine preference, suggesting that α6α4β2*-nAChRs are involved."( Differential roles of α6β2* and α4β2* neuronal nicotinic receptors in nicotine- and cocaine-conditioned reward in mice.
Bowers, MS; Brunzell, DH; Damaj, MI; Maldoon, PP; Marks, MJ; Maskos, U; McIntosh, JM; Sanjakdar, SS, 2015
)
0.42
" With this aim, 6 Murciano-Grandina dairy does during late lactation and 6 dry Manchega dairy ewes were orally dosed with 200 and 225 mg LiCl/kg BW, respectively."( Kinetics of lithium as a lithium chloride dose suitable for conditioned taste aversion in lactating goats and dry sheep.
Albanell, E; Caja, G; Guitart, R; Manuelian, CL; Rovai, M, 2015
)
0.72
" The animals were randomized into groups and were administered one of the following treatments: saline, PILO, saline+L-α-aminoadipic acid (L-AAA; one dosage tested), PILO+L-AAA, or PILO+L-methionine sulfoximine (three dosages tested)."( A sub-threshold dose of pilocarpine increases glutamine synthetase in reactive astrocytes and enhances the progression of amygdaloid-kindling epilepsy in rats.
Bai, XY; Chen, XM; Deng, DP; Li, SC; Liu, YX; Pan, XH; Sun, HL; Wang, CH; Wang, CY; Zhang, XL; Zhu, W, 2016
)
0.43
" In addition, both of cell proliferation and Six2 expression in MM cells declined when dosage reached high-concentration (50 mM)."( Six2 Is a Coordinator of LiCl-Induced Cell Proliferation and Apoptosis.
Chen, X; Gu, Y; Hao, J; Ju, P; Kanyomse, Q; Li, G; Li, Y; Liu, J; Liu, X; Liu, Y; Long, Y; Lyv, Z; Mao, Z; Ni, D; Wan, Q; Wang, R; Xiang, Y; Xie, Y; Zhang, J; Zhao, H; Zhao, Y; Zhou, Q; Zhou, Y, 2016
)
0.43
" Patients should be warned to avoid dosage errors and to take special care during concurrent illnesses and while taking other medications."( [Acute lithium poisoning: epidemiology, clinical characteristics, and treatment].
Burguera Vion, V; Del Rey, JM; Liaño, F; Montes, JM; Rivera-Gorrín, M; Rodao, JM; Saiz-Ruiz, J; Tenorio, M, 2017
)
0.46
"Clinical factors contributing to benzodiazepine failure in treating status epilepticus (SE) include suboptimal dosing and seizure duration."( Status epilepticus: Role for etiology in determining response to benzodiazepines.
Chester, SJ; Goodkin, HP; Hawk, KM; Joshi, S; Rajasekaran, K, 2018
)
0.48
"Previous studies have shown that several aryl hydrocarbon receptor (AHR) agonists, including β-naphthoflavone (BNF), elicit avoidance of novel food items in rodents, with this behavioral response displaying a similar dose-response to hepatic induction of CYP1A1."( Aryl hydrocarbon receptor is indispensable for β-naphthoflavone-induced novel food avoidance and may be involved in LiCl-triggered conditioned taste aversion in rats.
Mahiout, S; Pohjanvirta, R, 2019
)
0.51
" D-gal was given at a dosage of 300mg/ml/kg$ and animals received their respective treatment for 6 weeks [intraperitoneally (I."( Effect of lithium chloride on d-galactose induced organs injury: Possible antioxidative role.
Ayaz, MM; Bilal, K; Khaliq, S; Samad, N; Yasmin, F; Zaman, A, 2020
)
0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antimanic drugAntimanic drugs are agents used to treat bipolar disorders or mania associated with other affective disorders.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
inorganic chloride
lithium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Integrated breast cancer pathway9818
OSX and miRNAs in tooth development01

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency5.62340.35487.935539.8107AID624146
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.62280.001318.074339.8107AID926
arylsulfatase AHomo sapiens (human)Potency0.47751.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
D(1A) dopamine receptorHomo sapiens (human)Potency0.81990.02245.944922.3872AID488982
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency6.30960.01789.637444.6684AID588834
flap endonuclease 1Homo sapiens (human)Potency5.32330.133725.412989.1251AID588795
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency708.9730707.9460708.9730710.0000AID2301; AID2308
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.02000.00106.000935.4813AID943
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Cholecystokinin receptor type ARattus norvegicus (Norway rat)Potency710.0000710.0000710.0000710.0000AID2301
Gastrin/cholecystokinin type B receptorRattus norvegicus (Norway rat)Potency710.0000710.0000710.0000710.0000AID2301
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glycogen synthase kinase-3 betaHomo sapiens (human)IC50 (µMol)6.53000.00060.801310.0000AID1056787
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glycogen synthase kinase-3 betaHomo sapiens (human)EC50 (µMol)3,000.00000.20000.85001.5000AID82517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (73)

Processvia Protein(s)Taxonomy
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
ER overload responseGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of apoptotic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
epithelial to mesenchymal transitionGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell-matrix adhesionGlycogen synthase kinase-3 betaHomo sapiens (human)
glycogen metabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrion organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
dopamine receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of autophagyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-threonine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
viral protein processingGlycogen synthase kinase-3 betaHomo sapiens (human)
hippocampus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
establishment of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
maintenance of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of cell migrationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axon extensionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein ubiquitinationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of phosphoprotein phosphatase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule-based processGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to interleukin-3Glycogen synthase kinase-3 betaHomo sapiens (human)
regulation of circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of GTPase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of osteoblast differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen biosynthetic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cilium assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein autophosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of dendrite morphogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axonogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
excitatory postsynaptic potentialGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule cytoskeleton organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeGlycogen synthase kinase-3 betaHomo sapiens (human)
superior temporal gyrus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to retinoic acidGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandGlycogen synthase kinase-3 betaHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule anchoring at centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of cellular response to heatGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein localization to nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of long-term synaptic potentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein acetylationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to ciliumGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of dopaminergic neuron differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to amyloid-betaGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complex disassemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of type B pancreatic cell developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of mesenchymal stem cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of TOR signalingGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
insulin receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
protease bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
p53 bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine/threonine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ATP bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ubiquitin protein ligase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase A catalytic subunit bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
dynactin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau-protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
NF-kappaB bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
glutamatergic synapseGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrionGlycogen synthase kinase-3 betaHomo sapiens (human)
centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
plasma membraneGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
dendriteGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complexGlycogen synthase kinase-3 betaHomo sapiens (human)
presynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
postsynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
Wnt signalosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (53)

Assay IDTitleYearJournalArticle
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID118788Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 10 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID243255Inhibitory activity (20 mM) against Glycogen synthase kinase-3 beta, expressed as percent control2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds.
AID111838Compound was evaluated for the ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 40 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID605822Inhibition of GSK3 in granule cerebellar neurons assessed as increase of tau phosphorylation at 25 uM after 16 hrs by Western blot analysis2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds.
AID111826Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 1.25 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID111834Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 20.0 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID1765308Improvement in learning and spatial memory in mouse harboring APP/PSI/Tau assessed as improvement in trajectory at 100 mg/kg, po for 30 consecutive days and studied for 5 days by Morris water maze test relative to control2021European journal of medicinal chemistry, Oct-15, Volume: 222Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
AID111828Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 10.0 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID1563653Neuroprotective activity against amyloid beta (25 to 35 residues)-induced cell death in human SH-SY5Y cells assessed as increase in cell viability at 10 mM preincubated for 1 hr followed by amyloid beta (25 to 35 residues) addition and measured after 72 h2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases.
AID1056787Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors.
AID82517Effective concentration of compound against glycogen synthase kinase-3 in HEK293 cells2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3.
AID1477067Toxicity in Wistar rat assessed as induction of malaise at 0.4 M measured 30 mins for 2 days by conditioned taste aversion test2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
A Positive Allosteric Modulator of the Serotonin 5-HT
AID111830Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 2.5 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID118793Retention for passive avoidance learning in mice at dose 5 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID605823Inhibition of GSK3 in granule cerebellar neurons assessed as decrease of tau phosphorylation at Ser396 at 25 uM after 16 hrs by Western blot analysis2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds.
AID111841Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 5 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID1261852Inhibition of amphetamine-induced hypermotility in C57BL/6J mouse at 50 to 100 mg/kg, ip measured for 90 mins2015Journal of medicinal chemistry, Nov-25, Volume: 58, Issue:22
Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.
AID118787Retention for passive avoidance learning in mice at dose 1.25 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID1633450Inhibition of GSK3beta in human SH-SY5Y cells assessed as reduction in copper-induced tau hyperphosphorylation at 10 mM preincubated for 1 hr followed by copper addition and measured after 26 hrs by ELISA2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID118789Retention for passive avoidance learning in mice at dose 2.5 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID118792Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 40 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID1814365Cytotoxicity against human NB-4 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia.
AID111825Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 0.63 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID111843Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 80 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID118795Retention for passive avoidance learning in mice at dose 80 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID1261876Toxicity in C57BL/6J mouse amphetamine-induced hypermotility model assessed as reduction of spontaneous locomotor activity at 100 mg/kg, ip2015Journal of medicinal chemistry, Nov-25, Volume: 58, Issue:22
Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.
AID1563656Effect on cell proliferation in human SH-SY5Y cells at 1 to 10 mM measured after 1 hr by MTT assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases.
AID1543581Inhibition of GSK3bbeta in human SH-SY5Y cells assessed as reduction in human amyloid beta (25 to 35) peptide-induced tau hyperphosphorylation at Ser396 residue at 20 mM preincubated for 1 hr followed by amyloid beta-stimulation and measured after 6 hrs b2019European journal of medicinal chemistry, Apr-01, Volume: 167Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer's disease.
AID1814387Antiproliferative activity against human NB4-DR1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia.
AID243257Inhibitory activity (20 mM) against Glycogen synthase kinase-3 alpha, expressed as percent control2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID118785Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 0.63 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,741)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990697 (18.63)18.7374
1990's691 (18.47)18.2507
2000's1044 (27.91)29.6817
2010's1147 (30.66)24.3611
2020's162 (4.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 84.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index84.28 (24.57)
Research Supply Index8.28 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index154.70 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (84.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials45 (1.16%)5.53%
Reviews73 (1.88%)6.00%
Case Studies46 (1.18%)4.05%
Observational1 (0.03%)0.25%
Other3,718 (95.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]